Interferon β-1a reduces increased interleukin-16 levels in multiple sclerosis patients

Abstract

Reduction in increased IL-16 levels may be of relevance for the therapeutic effect of IFN-β1a in MS. Easily accessible IL-16 serum levels hold a potential as biomarker of treatment efficacy in MS.